3176 Share Price Performance
Recent 3176 News & Updates
No updates
Medigen Biotechnology Corp. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.19
- Gross Margin
- 59.90%
- Net Profit Margin
- -1.63%
- Debt/Equity Ratio
- 13.0%
Medigen Biotechnology Corp. Competitors
About 3176
- Founded
- 1999
- Employees
- n/a
- CEO
- WebsiteView website
Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cytotherapy, advanced nucleic acid testing, generic drugs, aesthetic medicine, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for head and neck cancer, and gastric cancer patients in the United States. Medigen Biotechnology Corp. was founded in 1999 and is headquartered in Taipei, Taiwan.
Taiwanese Market Performance
- 7 Days: 0.6%
- 3 Months: 12.7%
- 1 Year: 2.4%
- Year to Date: 2.3%
Over the last 7 days, the market has remained flat, although notably the Energy sector gained 9.2% in that time. Similarly, the market is flat for the past 12 months. As for the next few years, earnings are expected to grow by 13% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading